Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma

Outcomes for children and adolescents with relapsed and refractory Hodgkin lymphoma (HL) are poor, with ∼50% of patients experiencing a subsequent relapse. The anti-CD30 antibody–drug conjugate brentuximab vedotin improved progression-free survival (PFS) when used as consolidation after autologous s...

Descripción completa

Detalles Bibliográficos
Autores principales: Forlenza, Christopher J., Rosenzweig, Jaclyn, Mauguen, Audrey, Buhtoiarov, Ilia, Cuglievan, Branko, Dave, Hema, Deyell, Rebecca J., Flerlage, Jamie E., Franklin, Anna K., Krajewski, Jennifer, Leger, Kasey J., Marks, Lianna J., Norris, Robin E., Pacheco, Martha, Willen, Faye, Yan, Adam Paul, Harker-Murray, Paul D., Giulino-Roth, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338202/
https://www.ncbi.nlm.nih.gov/pubmed/36897253
http://dx.doi.org/10.1182/bloodadvances.2022009323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338202/
https://www.ncbi.nlm.nih.gov/pubmed/36897253
http://dx.doi.org/10.1182/bloodadvances.2022009323

Ejemplares similares